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Abstract
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Aims—To estimate the overall and cause-specific mortality in a population of African-Americans
and white Americans with a low socio-economic status who had young-onset insulin-treated
diabetes and had survived beyond the age of 40 years, and to examine whether any excess risk
varied according to age at diabetes onset.
Methods—Using the Southern Community Cohort Study, we conducted a mortality follow-up of
a cohort of mostly low-income participants aged 40–79 years (mean 50 years) at cohort entry with
insulin-treated diabetes diagnosed before age 30 years (n=475) and without diabetes (n=62 266).
Childhood onset was defined as diabetes diagnosed before age 20 years (n=162), while youngadulthood onset was defined as diabetes diagnosed between ages 20 and 29 years (n=313). Causespecific mortality was based on both underlying and contributing causes of death, obtained from
death certificates. Multivariable Cox analysis was performed.
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Results—During follow-up (mean 9.5 years), 38.7% of those with and 12.9% of those without
diabetes died. Compared with those without diabetes, increases in mortality rate were generally
similar among those with childhood- and young-adulthood-onset diabetes for deaths from: all
causes (childhood: hazard ratio 4.3, CI 3.3–5.5; young adulthood: hazard ratio 4.9, CI 4.0–5.8);
ischaemic heart disease (childhood: hazard ratio 5.7, CI 3.5–9.4; young adulthood: hazard ratio
7.9, CI 5.6–11.0); heart failure (childhood: hazard ratio 7.3, CI 4.2–12.7; young adulthood: hazard
ratio 5.4, CI 3.3–8.9); sepsis (childhood: hazard ratio 10.3, CI 6.1–17.3; young adulthood: hazard
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ratio 8.8, CI 5.7–13.5); renal failure (childhood: hazard ratio 15.1, CI 8.6–26.5; young adulthood:
hazard ratio 18.2, CI 12.3–27.1); respiratory disorders (childhood: hazard ratio 3.9, CI 2.3–6.7;
young adulthood: hazard ratio 5.3, CI 3.7–7.7); suicide/homicide/accidents (childhood: hazard
ratio 2.3, CI 0.72–7.0; young adulthood: hazard ratio 5.8, CI 3.4–10.2); and cancer (childhood:
hazard ratio 2.1, CI 0.98–4.4; young adulthood: hazard ratio 1.2, CI 0.55–2.5).
Conclusions—We observed high excess long-term mortality for all-cause, renal failure,
ischemic heart disease and heart failure mortality in African-American and white American people
with early-onset insulin-treated diabetes.

Introduction

Author Manuscript

Mortality rates among people with Type 1 diabetes have consistently been shown to be three
to five times higher than in the general population, even among people surviving to middle
age [1–6]. Limited information is available on the long-term survival experience of AfricanAmericans with Type 1 diabetes, or on white Americans with Type 1 diabetes in the lowest
income strata of the US population. Determining the critical age ranges at diabetes onset that
are associated with the greatest rates of end organ complications and the lowest rates of
survival can inform targeting of specific treatment practices in that age-diagnosis cohort,
both at onset of Type 1 diabetes and the critical years that follow. However, people
diagnosed with Type 1 diabetes and those surviving to middle age may provide unique
information on how age at diagnosis affects survival patterns in long-term survivors.
Additionally, how age of onset of Type 1 diabetes may affect survival in non-white people
and populations with limited education, income and access to healthcare can inform targeted
education, risk factor management and treatment practices. We therefore investigated allcause and cause-specific mortality in a population of African-American and white American
people with low socio-economic status (SES) who had survived to age 40 years, and also
whether any excess risk varied by age at Type 1 diabetes onset.

Author Manuscript

Methods

Author Manuscript

The Southern Community Cohort Study (SCCS) is a population-based study that was
designed to investigate causes of health disparities in the incidence and mortality of cancer
and other chronic diseases. Details of the rationale, study design and methods have been
described previously [7]. Briefly, between 2002 and 2009, >85 000 participants, aged 40–79
years, were recruited from community health centres (85%) and their surrounding
communities (15%) from 12 states in southeastern USA. Community health centres are
government-funded healthcare facilities offering basic healthcare services to the medically
underserved. All study procedures were approved by the institutional review boards of
Vanderbilt University Medical Center and Meharry Medical College.
After obtaining informed consent, information on medical history, lifestyle and demographic
factors was collected by in-person interview from community health centre-recruited
participants and by completion of the study questionnaire in the postal survey-recruited
participants. If a participant answered ‘yes’ to the question ‘Has a doctor ever told you that
you have diabetes or high blood sugar?’, he/she was asked questions about age at diabetes
diagnosis and medications currently taken to treat diabetes. Women were asked to exclude
Diabet Med. Author manuscript; available in PMC 2019 June 01.
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gestational diabetes in their reporting. A total of 17 750 individuals reported having a
physician diagnosis of diabetes, of whom 421 had a missing age of diabetes diagnosis. Of
the remaining 17 329 participants, 1411 were diagnosed before the age of 30 years (hereafter
referred to as ‘young-onset’). Five individuals with young-onset diabetes were excluded
from analysis because they reported not knowing whether they were using any diabetes
medication (n=2) or had missing information on diabetes medication use (n=3). Among
those diagnosed with young-onset diabetes, 475 reported using insulin as the only
hypoglycaemic agent at the time of enrolment into the SCCS, 242 reported using insulin
plus an additional hypoglycaemic agent, and 633 reported not being on insulin therapy. The
475 participants diagnosed with diabetes before the age of 30 years and reporting insulin as
their only form of anti-hyperglycaemic therapy at study enrolment formed the basis of our
‘presumed Type 1 diabetes’ cohort, hereafter referred to as ‘Type 1 diabetes’. Of these, 162
were diagnosed before the age of 20 years and formed our childhood-onset Type 1 diabetes
cohort and 313 were diagnosed between the ages of 20 and 29 years and formed our youngadulthood-onset cohort. Those reporting no history of physician-diagnosed diabetes at time
of enrolment into the SCCS formed our reference population (n=65 266).

Author Manuscript

Mortality status and underlying and contributing causes of death were determined from
linkages of the SCCS population with the National Death Index database, with mortality
censored on 31 December 2014. As data relying only on the underlying causes of death
listed on death certificates may substantially underestimate the impact of diabetes-related
complications on total mortality in individuals with diabetes, we used both the underlying
and contributing causes listed on the death certificates in determining cause-specific
mortality [8,9]. The specific causes of death investigated were ischaemic heart disease, heart
failure, renal disease, respiratory failure/arrest (respiratory disorders), sepsis, accidents and
cancer. The International Statistical Classification of Diseases and Related Health Problems
10th revision codes that were listed as either the underlying or contributing cause of death
and were used to define the above disease classifications can be found in the online
Supporting Information (Table S1).

Author Manuscript

The t-test and general linear models were used to test for differences in continuous variables
across the comparison groups and chi-squared tests were used to test for differences in
categorical data. Cox proportional hazards modelling, using age as the time scale, was used
to estimate hazard ratios for all-cause and cause-specific mortality by diabetes age at onset
group (childhood, young-adulthood) relative to those without diabetes. The multivariate
model included a term for self-reported race in addition to terms for diabetes group, sex,
education, annual household income, history of ischaemic heart disease, history of stroke/
transient ischaemic attack, history of smoking, and baseline health insurance coverage.
Because of sample size limitations in other racial/ethnic groups, effect modification by race
was assessed and race-specific analyses conducted among African-American and white
American people only. The criterion for statistical significance was a two-tailed P value of <
0.10 for multiplicative interaction, and <0.05 otherwise. Statistical analyses were conducted
using SAS version 9.4 (Cary, NC, USA).
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Results
The characteristics of the study participants according to Type 1 diabetes status are shown in
Table 1. Compared to those without diabetes, those with Type 1 diabetes were slightly
younger, more likely to be female, and had a much higher prevalence of comorbidities,
despite having a lower prevalence of history of smoking. Those with Type 1 diabetes were
also more likely to have a household annual income of <$15,000 per year, although only
those with childhood-onset Type 1 diabetes were more likely to have a lower than high
school education level. Characteristics of the study participants with Type 1 diabetes,
stratified by age at onset and race, are shown in Table S2.

Author Manuscript

Participants were followed for a mean of 9.5 years, with 8603 deaths recorded. Cumulative
mortality was 39.5% (n=64) among those with childhood-onset diabetes, 38.3% (n=120)
among those with young-adult-onset diabetes, and 12.9% (n=8419) among those without
diabetes. Figure 1 shows the contribution to mortality, stratified by diabetes group, of each
of the major causes of death in diabetes. Ischaemic heart disease and renal disease
contributed to the greatest number of deaths among those with young-adulthood-onset
diabetes, while heart failure and renal disease contributed to the greatest number of deaths
among those with childhood-onset diabetes. Accidents accounted for a greater percentage of
deaths among those diagnosed with diabetes in their 20s than among those diagnosed in
childhood or those without diabetes. Cancer accounted for >30% of all deaths among those
without diabetes. By contrast, cancer contributed to ~10% of all deaths in those with
childhood-onset diabetes and to only ~5% of all deaths among those with young-adulthoodonset diabetes.

Author Manuscript

Absolute mortality rates, adjusted for age, for all-cause mortality and each of the major
causes of death in Type 1 diabetes are presented in Table 2. Overall, mortality rates were
highest for respiratory disorders, followed by ischaemic heart disease, heart failure, sepsis
and renal disorders. The mortality rates tended to be higher among white Americans than
African-Americans, except for sepsis, but differences between childhood- and youngadulthood-onset groups were not notable, except for heart failure, for which rates were
higher among childhood-onset cases.

Author Manuscript

Multivariable adjusted relative mortality rates among adults with Type 1 diabetes compared
with those without diabetes are shown in Fig. 2. Although mortality rates, ranging from
four- to 18-fold higher, were generally similar among those with childhood-onset and
young-adulthood-onset Type 1 diabetes vs those without diabetes, mortality rates were
slightly higher for all causes, ischaemic heart disease, renal disorders, respiratory disorders
and accidents among those with young-adulthood-onset Type 1 diabetes. Mortality rates
were slightly higher for heart failure, sepsis and cancer among those with childhood-onset
diabetes.
When stratified by race, hazard ratios for all-cause and cause-specific mortality between
those with and without diabetes were generally slightly higher among those with youngadulthood-onset Type 1 diabetes among African-American people, but slightly higher for
those with childhood-onset Type 1 diabetes among white American people (Fig. 3). This
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was particularly noticeable for renal failure mortality (race × age at diagnosis group
interaction P =0.005). African-American people with childhood-onset diabetes had a 10
times greater risk of mortality from renal failure than African-American people without
diabetes, whereas for African-Americans diagnosed with Type 1 diabetes in their 20s this
excess risk was 15-fold. For white Americans with childhood-onset diabetes, the risk of
renal failure mortality was 50 times greater than for white Americans without diabetes.
White Americans diagnosed with diabetes in their 20s were at a 34-fold greater risk than
white Americans without diabetes. Multivariable adjusted relative mortality rates, stratified
by race, between adults with Type 1 diabetes and those without diabetes are shown in Fig. 3.

Discussion

Author Manuscript

Limited information is available on the long-term survival experience of African-American
people with Type 1 diabetes, or on white American people with Type 1 diabetes in the
lowest income strata of the US population. We observed high excess all-cause and causespecific mortality rates in our Type 1 diabetes cohort compared with people without diabetes
who had a similarly low SES. Race- and age-specific analyses showed that this was true
among both African-Americans and white Americans and whether diagnosed with diabetes
in childhood or young adulthood. Renal failure and heart failure mortality were common,
with rates of mortality from renal failure up to 21 and 61 times higher, respectively, among
African-Americans with young-adult onset and white Americans with childhood-onset Type
1 diabetes compared with their counterparts without diabetes with similarly low SES.

Author Manuscript

Reports on all-cause mortality among African-Americans with Type 1 diabetes have come
from the New Jersey 725 cohort [10], the United States Virgin Islands Type 1 (USVT1)
diabetes registry cohort [11], and the Allegheny County, Pennsylvania registry of childhoodonset Type 1 diabetes [6]. In the three cohorts, mortality rates were ~6–20 times higher than
in the general population. While these excess rates were higher than the excess rate observed
in the present study population, our cohort was substantially older and had a longer duration
of diabetes when follow-up was initiated. The marked acceleration of mortality starting in
middle age in the background population probably attenuated excess mortality rates
attributable to Type 1 diabetes in the present study population, which was a survival
population, with entry into the SCCS starting at age 40 years. To our knowledge, the present
study is the first to report on the survival experience, or more specifically, cause-specific
mortality of African-American people with presumed Type 1 diabetes who have lived to at
least middle-adulthood. Our data suggest that, for individuals diagnosed with Type 1
diabetes in childhood or young adulthood, mortality rates surge in middle age.

Author Manuscript

Overall, the survival experience of African-Americans and white Americans in our
population with presumed Type 1 diabetes was similar for all-cause, ischaemic heart disease,
and renal disorders mortality for each of the four age-at-diabetes-onset and race groups. This
is in contrast to the much higher rates for these outcomes among African-American people
in the Allegheny County registry [12]. We believe the differences observed between these
two studies are attributable to the greater differential in SES between African-Americans in
the Allegheny cohort than those in the SCCS cohort. The majority of the SCCS cohort was
recruited from federally qualified health centres and thus both African-American and white
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people had similarly low SES. By contrast, no such restrictions were made on the Allegheny
County registry population which reflected the background population in which white
people generally have a much higher SES than African-American people. Among people
with Type 1 diabetes, low SES has been shown to increase the risk of all-cause mortality
[13,14] and mortality from cardiovascular disease [14] 2.5- to 3.5-fold.

Author Manuscript

Ischaemic heart disease was the leading contributor to mortality in the people with Type 1
diabetes in the present study, contributing to ~30% of all deaths (vs 17% in those without
diabetes), with hazard ratios six to eight times higher among those with Type 1 diabetes than
in those without, findings in line with other reports in Type 1 diabetes [12,15]; however,
although ischaemic heart disease was the leading contributor to mortality in our population
with Type 1 diabetes, renal failure accounted for the greatest relative increases in mortality
compared with the SCCS general population. We observed rates 10- to 15-fold higher
among African-American people and 30- to 50-fold higher among white American people
compared with the race-specific SCCS general population, consistent with the 100-fold
increases in renal disease mortality rates at younger ages observed in the Allegheny County
registry study [16]. Another important finding of the present study was that absolute
mortality rates to which renal disease was a contributor were essentially similar in AfricanAmerican and white American people with Type 1 diabetes, suggesting that Type 1 diabetes
levels the playing field with regard to the impact of renal disease for African-Americans and
white Americans.

Author Manuscript

We did not find marked differences in mortality outcomes according to age at diabetes
diagnosis; mortality rates were essentially similar in the two age-at-diabetes-diagnosis
cohorts, regardless of race. While this may be attributable to left truncation and the resulting
survival bias among those diagnosed with diabetes during childhood, i.e. people had to live
to age 40 years to enter our study and those diagnosed at a younger age would have had a
longer exposure to diabetes, the present data may also suggest that duration of diabetes does
not play as strong a role in diabetes complications as commonly thought. Some authors have
reported an increased risk of complications-related mortality among those diagnosed with
Type 1 diabetes in later adolescence and young-adulthood relative to those diagnosed in
childhood [17], but this has not been consistently observed [15].

Author Manuscript

Regardless of the age of diagnosis, there was a very high risk of mortality overall and for
most of the specific causes of death. Our findings are consistent with results from most
recent population studies in people with Type 1 diabetes [18–20]; however, our results are
inconsistent with recent data coming from the Diabetes Control and Complications Trial/
Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study, in which
mortality rates were non-significantly lower in the formerly intensive therapy group while
modestly, but significantly, higher in the conventional therapy group compared with the US
general population [21]. The discrepancy between the present results and those of the
DCCT/EDIC study is probably attributable to the selection criteria used by the DCCT/EDIC
study, the much higher than national average SES of that cohort [22], and the very extensive
yearly clinical examinations carried out in that study. Nevertheless, the impact of the DCCT/
EDIC study results on patient treatment is likely be decreased mortality in future cohorts of
African-American and white-American people with Type 1 diabetes who have low incomes.
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When the SCCS was first conceived, the low-income segment of the US population had
rarely been used in large epidemiology cohort studies. In addition to controlling for racial
differences in SES, by focusing on the low-income segment of the US population the study
aimed to assess the particular chronic disease health challenges of this population. Little
information is available on the low-income segment of the Type 1 diabetes population; a
major strength of the present study is its large sample size, which included both AfricanAmerican and white American people with low incomes. Another strength is the relatively
large number of African-Americans with presumed Type 1 diabetes, the largest AfricanAmerican cohort to date with long duration of early-onset, insulin-treated diabetes. By
recruiting predominantly from federally qualified health centres, our African-American and
white American participants were more likely to have similar access to healthcare.

Author Manuscript
Author Manuscript

Classification of diabetes in our cohort was based on self-report of a physician diagnosis,
while classification of diabetes type, specifically Type 1 diabetes, was based on age at
diabetes diagnosis and the use of insulin as the only form of anti-hyperglycaemic therapy. A
weakness of the present study was the likely less than perfect specificity in our presumed
Type 1 diabetes cohort. Our population was diagnosed with diabetes on average in the mid
to late 1970s but not recruited to the study until ~30 years later; thus, there is the likelihood
of misclassification of diabetes type for some participants. The average BMI around the time
of average age of diabetes diagnosis for both our African-American and white American
participants was more consistent with a Type 1 than Type 2 diabetes population, nevertheless
we cannot not rule out other diabetes types. Another limitation is that cause-specific
mortality was based on death certificate data and the study therefore includes the limitations
inherent in reliance on non-adjudicated death certificate data [8,23]. Finally, survival bias
attributable to left truncation might be viewed as a weakness of the present study because the
participants were not followed from age at diabetes diagnosis but had to survive until age 40
years to enter the study. However, the objective of the present study was to describe the
mortality experience of people surviving to middle age and beyond with Type 1 diabetes and
to investigate whether the age at diabetes diagnosis had any impact on survival.

Author Manuscript

The SCCS is one of the nation’s largest investments in health disparities research. Even
when compared with individuals with similarly low incomes, we observed high excess longterm mortality rates for renal disease, ischaemic heart disease and heart failure in AfricanAmerican and white American people with early-onset insulin-treated diabetes; this excess
risk was particularly striking for African-American people diagnosed in their 20s and for
white people diagnosed in childhood. These high excess rates are likely to be greater still
when compared with the general US population [5]. Given our observed high morbidity
rates, manifested by the high prevalence of diabetes complications and the high mortality
rates during the prime adult working years, efforts aimed at minimizing complication rates
among people with low incomes with presumed Type 1 diabetes may minimize the burden
on the public healthcare system.
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What’s new?
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•

Little information is available on the mortality outcomes of African-American
and white American people with low incomes who have a long duration of
Type 1 diabetes.

•

The majority of the participants in the present study were recruited from
federally qualified health centres, which are government-funded health
centres offering basic health services to the poorest population in the USA.

•

Leading causes of death at age ≥40 years among survivors of early-onset
diabetes were ischaemic heart disease and renal disease: mortality rates for
these specific outcomes were seven- and 18-fold higher compared with those
without diabetes.

•

A greatly elevated mortality rate during their prime working years persists
among low-income African-American and white Americans with Type 1
diabetes.

•

Little difference in mortality was found between those with childhood-onset
vs young-adulthood-onset diabetes, suggesting that diagnosis at any early age
conveys elevated long-term risk.
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FIGURE 1.

Contribution to mortality of each of the major contributing causes of death in Type 1
diabetes. Mortality event numbers by diabetes onset were as follows: ischaemic heart
disease: childhood onset n=17, young adulthood onset n=36, no diabetes n=1380; heart
failure: childhood onset n=13, young adulthhood onset n=16, no diabetes n=843; renal
disease: childhood onset n=14, young adulthood onset n=29, no diabetes n=438; sepsis:
childhood onset n=17, young adulthood onset n=22, no diabetes n=841; respiratory
disorders: childhood onset n=13, young adulthood onset n=29, no diabetes n=2053; cancer:
childhood onset n=7, young adulthood onset n=7, no diabetes n=2569; accidents: childhood
onset n=3, young adulthood onset n=15, no diabetes n=871.
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FIGURE 2.

Multivariable adjusted risk of all-cause and cause-specific mortality for Type 1 diabetes
compared with those without diabetes, odds ratio (OR) and 95% CI. Solid black lines=
childhood onset Type 1 diabetes. Dashed lines = young-adulthood-onset Type 1 diabetes.
Multivariable analyses additionally controlled for sex, race, hypercholesterolaemia,
hypertension, prior ischaemic heart disease, prior stroke/transient ichaemic attack, history of
smoking, education, annual household income and health insurance coverage.
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FIGURE 3.

Author Manuscript

Multivariable adjusted risk of all-cause and cause-specific mortality for Type 1 diabetes
compared with those without diabetes stratified by race, odds ratio (OR) and 95% CI. Solid
black lines= childhood-onset Type 1 diabetes. Dashed lines = young-adulthood-onset Type 1
diabetes. Multivariable analyses additionally controlled for sex, hypercholesterolaemia,
hypertension, prior ischaemic heart disease, prior stroke/transient ischaemic attack, history
of smoking, education, annual household income and health insurance coverage. P value for
race × age at diabetes diagnosis interaction term=0.005 for renal disease mortality. P value
for race × age at diabetes diagnosis interaction term=0.007 for cancer mortality. AA, xxx;
EA,.

Author Manuscript
Diabet Med. Author manuscript; available in PMC 2019 June 01.

Conway et al.

Page 14

Table 1

Author Manuscript

Baseline characteristics of the Southern Community Cohort Study ‘Type 1 diabetes’ cohort, stratified by age at
diabetes diagnosis
Childhood-onset Type 1 diabetes
N=162

Young-adulthood-onset Type 1
diabetes
N=313

No diabetes
N=65 266

Age at baseline, years

50.2 ± 7.9*

49.7 ±7.1‡

51.6 ± 8.6

Age at diagnosis, years

12.6 ± 5.7

25.0 ± 2.9

Diabetes duration, years

37.5 ± 9.6

24.7 ± 7.5

Sex: female, n (%)

69.1 (112)†

64.9 (203)*

57.9 (37 790)

White

35.4 (57)

23.6 (73)

31.1 (20 168)

African-American

62.1 (100)

73.9 (229)

65.0 (42 159)

2.5 (4)

2.6 (8)

3.9 (2552)

24.1 (21.3–28.1)§

24.9 (21.5–28.8)§

22.1 (19.3–24.8)

30.1 (25.3–36.3)†

31.0 (26.4–36.4)§

28.1 (24.3–32.9)

Prior ischaemic heart disease, n (%)

24.8 (40)§

18.5 (58)§

5.2 (3418)

Prior stroke, n (%)

19.3 (31)§

12.1 (38)§

5.3 (3443)

Cataracts, n (%)

30.4 (49)§

19.0 (59)§

7.2 (4666)

Glaucoma, n (%)

11.8 (19)§

10.6 (33)§

2.8 (1816)

Hypertension, n (%)

64.8 (105)§

78.9 (247)§

48.1 (31 395)

High cholesterol, n (%)

48.8 (79)§

53.5 (167)§

27.9 (18 188)

Ever smoker, n (%)

58.8 (94)

52.6 (164)§

65.3 (42 254)

<$15,000

71.3 (114)

66.8 (207)

53.4 (34 322)

$15,000–$24,999

13.1 (21)

21.3 (66)

21.2 (13 644)

$25,000–$49,000

8.8 (14)

8.1 (25)

14.7 (9438)

≥$50,000

6.9 (11)

3.9 (12)

10.7 (6889)

11.2 (18)*

8.4 (26)

7.0 (4544)

Race, n (%)

Author Manuscript

Other races
Median (IQR) BMI at age 21 years,

kg/m2

Median (IQR) BMI at study baseline,

kg/m2

Author Manuscript

Annual household income**, n (%)

Education <12 years

Data are expressed as mean ± SD, unless otherwise indicated.

*

P<0.05,

†

P<0.01,

‡

Author Manuscript

P<0.001 and

§

P<0.0001 compared with those without diabetes.

Table probability for differences in race category <0.05.

**

Table probability for differences in income category <0.0001.
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159.57

White

30.78

21.47

156.93

699.30

140.80

141.00

African-American

No diabetes

White

African-American

190.26

104.60

Ischaemic heart disease

550.98

763.17

White

Young-adulthood-onset Type 1 diabetes

550.36

African-American

Childhood-onset Type 1 diabetes

All-cause

14.63

15.54

70.61

66.34

335.47

135.54

Heart failure

4.37

9.20

141.21

122.09

150.72

135.01

Renal disease

51.57

31.35

106.20

117.94

378.82

78.87

Respiratory disorders

Author Manuscript

Age-adjusted mortality rates per 10 000 person-years

13.09

15.33

74.08

203.10

145.78

126.20

Sepsis

44.82

45.18

111.00

5.29

70.99

58.08

Cancer

21.26

11.98

71.36

158.87

0

43.96

Accidents
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